Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 72162-1276

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 72162-1276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (30406488 Figure 01)

Chemical structure of donepezil hydrochloride showing its molecular framework including methoxy groups, a piperidine ring, and a benzyl group with an associated hydrochloride component.*

FDA Label Image

Figure2 (30406488 Figure 02)

A line graph depicting ADAS-cog change from baseline over weeks of drug treatment for Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day doses compared to placebo. The y-axis shows mean change with standard error, indicating clinical improvement and decline, while the x-axis shows treatment duration in weeks up to 24 with a placebo period. Data points show trends in cognition changes for each group.*

FDA Label Image

Figure-03 (30406488 Figure 03)

A cumulative percentage of patients graph showing changes from baseline in ADAS-cog scores for Donepezil Hydrochloride Tablets at 5 mg/day and 10 mg/day doses compared to placebo. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients, illustrating the distribution of cognitive changes in each treatment group.*

FDA Label Image

Figure-04 (30406488 Figure 04)

A bar chart titled with CIBIC-plus Rating on the x-axis and Percentage of Patients on the y-axis. It compares the percentage of patients experiencing different degrees of improvement or worsening across three groups: Donepezil Hydrochloride Tablets 10 mg/day, Donepezil Hydrochloride Tablets 5 mg/day, and Placebo. Categories range from Markedly Improved to Markedly Worse, showing distribution of patient outcomes by treatment group.*

FDA Label Image

Figure-05 (30406488 Figure 05)

A line graph illustrating ADAS-cog mean change from baseline with standard error over 15 weeks of treatment, comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo tablets. The x-axis shows weeks of drug treatment and placebo period; the y-axis shows ADAS-cog change with clinical improvement and decline labeled.*

FDA Label Image

Figure-06 (30406488 Figure 06)

A cumulative percentage graph showing patients' change from baseline in ADAS-cog scores for three treatment groups: Placebo, Donepezil Hydrochloride Tablets 5 mg/day, and Donepezil Hydrochloride Tablets 10 mg/day. The graph plots cumulative percentage of patients against change in ADAS-cog scores, with vertical lines at -7 and -4 points and a data table summarizing percentage of patients achieving specific score changes by treatment group.*

FDA Label Image

Figure-07 (30406488 Figure 07)

A bar chart showing the percentage of patients with various levels of improvement or worsening, comparing Donepezil Hydrochloride Tablets at 10 mg/day, 5 mg/day, and placebo. Categories on the X-axis are: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The Y-axis represents the percentage of patients.*

FDA Label Image

08 (30406488 Figure 08)

A line graph showing SIB (Severe Impairment Battery) change from baseline mean ± SE over 6 months of drug treatment comparing Donepezil Hydrochloride Tablets 10 mg/day versus placebo. The graph illustrates clinical improvement with Donepezil and clinical decline with placebo over time.*

FDA Label Image

09 (30406488 Figure 09)

A line graph depicting the cumulative percentage of patients versus SIB change from baseline. It compares Donepezil Hydrochloride Tablets 10 mg/day (black circles) to placebo (open squares), showing patient response distributions for each treatment over a range of SIB changes.*

FDA Label Image

10 (30406488 Figure 10)

A line graph showing mean change from baseline in ADCS-ADL scores over six months of drug treatment. It compares Donepezil Hydrochloride Tablets 10 mg/day and placebo, indicating clinical improvement or decline on the vertical axis and months of treatment on the horizontal axis. The Donepezil group shows less decline over time than the placebo group.*

FDA Label Image

11 (30406488 Figure 11)

A line graph showing the cumulative percentage of patients on the vertical axis and ADCS-ADL change from baseline on the horizontal axis, comparing Donepezil Hydrochloride tablets 10 mg/day and placebo. The graph plots cumulative patient response with circles representing Donepezil Hydrochloride and squares for placebo, illustrating changes in ADCS-ADL scores from baseline.*

FDA Label Image

12 (30406488 Figure 12)

A line graph showing the change from baseline in SIB (Severe Impairment Battery) scores over 24 weeks of drug treatment with Donepezil Hydrochloride Tablets at doses of 23 mg/day and 10 mg/day. The graph includes LS mean (± SE) changes, with the 23 mg/day group showing greater improvement over time compared to the 10 mg/day group. Axes are labeled for weeks of drug treatment (x-axis) and SIB change from baseline (y-axis).*

FDA Label Image

13 (30406488 Figure 13)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride Tablets 23 mg/day and 10 mg/day by SIB change from baseline. The x-axis represents SIB change from baseline, while the y-axis represents the cumulative percentage of patients. Two curves show patient responses at these dosages.*

FDA Label Image

14 (30406488 Figure 14)

A bar chart comparing the percentage of patients receiving Donepezil Hydrochloride Tablets 23 mg/day versus 10 mg/day across different CIBIC-plus Ratings, including categories from Markedly Improved to Markedly Worse. The chart shows patient distribution by response to treatment dose levels.*

FDA Label Image

15 (30406488 Figure 15)

FDA Label Image

Label (Lbl721621276)

Donepezil Hydrochloride Tablets, USP 23 mg film-coated tablets, in a package containing 30 tablets. The label includes storage instructions, manufacturer (TWi Pharmaceuticals, Inc.), and relabeler information (Bryant Ranch Prepack, Inc.). The product is for oral use and is prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.